Skip to main content
. Author manuscript; available in PMC: 2011 Mar 2.
Published in final edited form as: Nat Immunol. 2010 Aug 1;11(9):836–845. doi: 10.1038/ni.1914

Figure 4. TACI binds MyD88 through a THC domain.

Figure 4

(a) Scheme of WT TACI and D1-D7 GST-TACI deletion mutants. Numbers, carboxy-terminal residues; TD, transmembrane domain; HCD, highly conserved domain. Complete TACI sequence shown in Supplementary Fig. S8. (b) Immunoprecipitation (IP) of 2E2 B cell lysates with GST, WT GST-TACI, or GST-TACI deletion mutants followed by immunoblotting (IB) of MyD88, TRAF2, TRAF5, TRAF6, CAML, or GST. kD, kilodaltons. (c) NF-κB and AP1 reporter assays in 293 cells expressing no TACI, WT TACI, D3 TACI or D4 TACI. Bottom gel, IB of TACI from total lysates. (d) Site-directed mutations in the THC domain. Upper numbers, residue positions; red crosses, substitutions; purple box, MyD88-binding site (BS). (e) IP of 2E2 B cell lysates with WT GST-TACI or GST-TACI site-directed mutants followed by IB of MyD88, TRAF2, TRAF5, TRAF6, CAML, or GST. (f) NF-κB and AP1 reporter assays in 293 cells expressing no TACI, WT TACI, or TACI site-directed mutants. Bottom gel, IB of TACI from total cell lysates. *P < 0.05 and ** P < 0.005 (one-tailed unpaired Student’s t-test). The data shown are from one of three experiments giving similar results (c,f) or summarize three experiments (d,g; error bars, SEM).